Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449)

作者：Meani Rowena E^*; Lim Shueh Wen; Chang Anne Lynn S; Kelly John W

来源：Australasian Journal of Dermatology, 2014, 55(3): 218-221.

DOI：10.1111/ajd.12196

• advanced BCC
• basal cell carcinoma (BCC)
• chemoresistance
• Hedgehog inhibitor
• metastatic BCC
• secondary resistance
• vismodegib

Vismodegib (GDC-0449, Genentech, USA), a small molecule inhibitor of the Hedgehog signalling pathway, has potent anti-tumour activity in advanced basal cell carcinoma (BCC). We report a case of a 67-year-old Australian man with metastatic BCC including pulmonary disease with malignant effusion who showed a dramatic complete response to vismodegib but subsequently experienced a recurrence of pulmonary disease, indicative of chemoresistance to vismodegib. This case is the first to illustrate chemoresistance in a patient with metastatic BCC, and demonstrates the need for closely monitoring metastatic BCC patients even after an apparently complete response.

• 出版日期2014-8